Ceftolozane/tazobactam vs meropenem for febrile neutropenia with ESBL risk
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a fever and a low white blood cell count (febrile neutropenia).
- You are either colonized with a resistant bacteria called ESBL, or you've taken certain strong antibiotics (like cephalosporins or piperacillin/tazobactam) for at least 2 days in the last month.
- You have not been found to carry bacteria that are resistant to the study drugs (carbapenems or ceftolozane/tazobactam).
- You have not used carbapenem antibiotics (like meropenem) for at least 2 days in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
This trial compares two antibiotics (ceftolozane/tazobactam vs. piperacillin/tazobactam) for treating a bloodstream infection in people with blood cancer who have a very low white blood cell count and a fever. The goal is to see which antibiotic works better.
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial tests whether the antibiotic cefotetan works as well as or better than standard treatments for E. coli bloodstream infections. You may be eligible if you have a confirmed E. coli infection in your blood that started in your urinary or genital area, and you have just started antibiotics in the hospital.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
Hear when a new Febrile Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.